文献速递冠心病血脂与心血管预防

替格瑞洛两种剂量方案与氯吡格雷在稳定性冠心病PCI患者中的比较研究

Study of Two Dose Regimens of Ticagrelor Compared With Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention for Stable Coronary Artery Disease.
PubMed 文献 · Circulation · 2018-07-24

本研究在180例计划行择期PCI的稳定性冠心病患者中,随机比较标准氯吡格雷方案与替格瑞洛90mg或60mg每日两次(均予180mg负荷量)对腺苷摄取和血小板抑制的影响。结果发现替格瑞洛两种维持剂量均未影响细胞腺苷摄取或血浆腺苷浓度,但均比氯吡格雷产生更强且更一致的血小板抑制,高血小板反应性比例显著更低,而PCI后肌钙蛋白释放无差异。

要点

  • 替格瑞洛60mg或90mg每日两次均未影响细胞腺苷摄取及血浆腺苷浓度。
  • 替格瑞洛两种剂量均比氯吡格雷血小板抑制更强且更一致,高血小板反应性更少。
  • 替格瑞洛与氯吡格雷相比PCI后肌钙蛋白释放无显著差异。

核心结论

  • 替格瑞洛60mg或90mg每日两次维持治疗1个月对细胞腺苷摄取和系统血浆腺苷浓度无 detectable 影响。
  • 替格瑞洛两种方案均比氯吡格雷产生更强且更一致的血小板抑制,但未明显影响PCI后肌钙蛋白释放。

研究设计与样本

  • 单中心随机对照研究,180例阿司匹林治疗的稳定性冠心病患者按1:1:1随机分为标准氯吡格雷方案、替格瑞洛90mg每日两次(T90)或60mg每日两次(T60),后两者均予180mg负荷量。

主要发现

  • 1个月给药后,替格瑞洛两种剂量与氯吡格雷相比对体外腺苷摄取无影响(15秒残余腺苷均值±SD:氯吡格雷0.274±0.101 µmol/L;T90 0.278±0.134 µmol/L;T60 0.288±0.149 µmol/L;P=0.37)。
  • 其他时间点体外腺苷摄取及血浆腺苷浓度亦无影响(所有P>0.1)。
  • 替格瑞洛两种维持剂量均比氯吡格雷血小板抑制更强且更一致(1个月VerifyNow P2Y12反应单位均值±SD:给药前,T60 62±47,T90 40±38,氯吡格雷181±44;给药后,T60 34±30,T90 24±21,氯吡格雷159±57;替格瑞洛 vs 氯吡格雷所有P<0.0001)。
  • 高血小板反应性(VerifyNow P2Y12反应单位>208)在1个月给药后T60、T90和氯吡格雷组分别为0%、0%和21%。
  • 高敏肌钙蛋白T中位数(四分位距)增加:氯吡格雷16.9(6.5-46.9)ng/L,T60 22.4(5.5-53.8)ng/L,T90 17.7(8.1-43.5)ng/L(P=0.95)。

临床怎么用

  • 在稳定性冠心病择期PCI患者中,替格瑞洛60mg或90mg每日两次均可提供比氯吡格雷更强且更一致的血小板抑制。
  • 替格瑞洛对腺苷摄取无影响,提示其临床获益机制可能不主要通过腺苷途径。
  • 替格瑞洛60mg每日两次可能呼吸困难更少,但需进一步验证。

局限性

  • 单中心研究,样本量有限(180例随机,162例接受PCI)。
  • 仅评估1个月时的药效动力学指标,未报告临床硬终点。
  • 原文未报告P值以外的统计细节及盲法信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ticagrelor has superior efficacy to clopidogrel in the management of acute coronary syndromes but has not been assessed in patients undergoing percutaneous coronary intervention for stable coronary artery disease. We compared the pharmacodynamic effects of ticagrelor and clopidogrel in this stable population. METHODS: One hundred eighty aspirin-treated stable coronary artery disease patients, who were planned to undergo elective percutaneous coronary intervention in a single center, were randomized 1:1:1 to either a standard clopidogrel regimen or 1 of 2 regimens of ticagrelor, either 90 mg (T90) or 60 mg twice daily (T60), both with a 180 mg loading dose. Cellular adenosine uptake was assessed, at the time of the procedure and pre- and postdose at 1 month, by adding adenosine 1 µmol/L to aliquots of anticoagulated whole blood and mixing with a stop solution at 0, 15, 30, and 60 seconds, then measuring residual plasma adenosine concentration by high-performance liquid chromatography. Systemic plasma adenosine concentration and platelet reactivity were assessed at the same timepoints. High-sensitivity troponin T was measured pre- and 18 to 24 hours postpercutaneous coronary intervention. RESULTS: One hundred seventy-four patients underwent an invasive procedure, of whom 162 received percutaneous coronary intervention (mean age 65 years, 18% female, 21% with diabetes mellitus). No effect on in vitro adenosine uptake was seen postdose at 1 month for either ticagrelor dose compared with clopidogrel (residual adenosine at 15 seconds, mean±SD: clopidogrel 0.274±0.101 µmol/L; T90 0.278±0.134 µmol/L; T60 0.288±0.149 µmol/L; P=0.37). Similarly, no effect of ticagrelor on in vitro adenosine uptake was seen at other timepoints, nor was plasma adenosine concentration affected (all P>0.1). Both maintenance doses of ticagrelor achieved more potent and consistent platelet inhibition than clopidogrel (VerifyNow P2Y12 reaction units, 1 month, mean±SD: predose, T60: 62±47, T90: 40±38, clopidogrel 181±44; postdose, T60: 34±30, T90: 24±21, clopidogrel 159±57; all P<0.0001 for ticagrelor versus clopidogrel). High platelet reactivity was markedly less with both T60 and T90 compared with clopidogrel (VerifyNow P2Y12 reaction units>208, 1 month postdose: 0%, 0%, and 21%, respectively). Median (interquartile range) high-sensitivity troponin T increased 16.9 (6.5-46.9) ng/L for clopidogrel, 22.4 (5.5-53.8) ng/L for T60, and 17.7 (8.1-43.5) ng/L for T90 (P=0.95). There was a trend toward less dyspnea with T60 versus T90 (7.1% versus 19.0%; P=0.09). CONCLUSIONS: Maintenance therapy with T60 or T90 had no detectable effect on cellular adenosine uptake at 1 month, nor was there any effect on systemic plasma adenosine levels. Both regimens of ticagrelor achieved greater and more consistent platelet inhibition than clopidogrel but did not appear to affect troponin release after percutaneous coronary intervention. CLINICAL TRIAL REGISTRATION: URL: https://www. CLINICALTRIALS: gov. Unique identifier: NCT02327624.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Orme RC, Parker WAE, Thomas MR, et al. Study of Two Dose Regimens of Ticagrelor Compared With Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention for Stable Coronary Artery Disease. Circulation. 2018. PMID: 29930021. doi:10.1161/CIRCULATIONAHA.118.034790

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。